| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3979406 | Bulletin du Cancer | 2010 | 11 Pages |
Abstract
Phase I dose finding method for molecularly targeted agents should continue to identify the MTD, but the dose recommended for phase II trials should not be systematically defined as the MTD and should incorporate other endpoints. In particular, more sensitive and more discriminatory endpoints are necessary. They needn't be good surrogate of the clinical benefit, but they should allow for ranking several doses. Experience from other medical specialties, such as phase II dose-ranging trials could be considered.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Paoletti X., Postel-Vinay S., Servois V., Doussau A., Ollivier L., Le Tourneau C.,